First, despite the majority of published studies illustrating that the PD-1/PD-L1 axis serves a profibrotic role in IPF and pharmaceutical intervention of this pathway could alleviate pulmonary fibrosis, all results were obtained based on murine studies, and the evidence from clinical studies remains lacking. This evidence concerns the gene RPL17 and idiopathic pulmonary fibrosis.